

Supplemental Material

Supplemental Table

| | MESA Cohort* (n=4967) | Subcohort (n=322) | P Value |
|--|--------------------------|----------------------|---------|
| Age, years | 61.4 ± 10.1 | 61.2 ± 10.3 | 0.74 |
| Male, % | 47.6 | 48.4 | 0.77 |
| Ethnicity, % | | | 0.11 |
| White | 38.9 | 36.3 | |
| Chinese | 13.1 | 9.6 | |
| Black | 25.7 | 27.6 | |
| Hispanic | 22.3 | 26.4 | |
| Systolic blood pressure, mmHg | 125.3 ± 21.3 | 125.9 ± 21.4 | 0.62 |
| Diastolic Blood pressure, mmHg | 71.8 ± 10.3 | 71.6 ± 10.0 | 0.61 |
| Hypertension, % | 42.2 | 45.3 | 0.28 |
| Medications for hypertension, % | 35.1 | 39.4 | 0.11 |
| Pulse rate, beats/min | 62.9 ± 9.4 | 63.4 ± 9.4 | 0.29 |
| Body mass index, kg/m ² | 27.7 ± 4.9 | 27.7 ± 4.9 | 0.78 |
| Smoking, % | | | 0.45 |
| Never | 51.5 | 49.7 | |
| Former | 35.7 | 35.1 | |
| Current | 12.8 | 15.2 | |
| Diabetes, % | 11.6 | 12.1 | 0.99 |
| LV ejection fraction, % | 69 ± 7 | 69 ± 7 | 0.89 |
| LV mass, g | 145 ± 39 | 144 ± 37 | 0.52 |
| NT-pro BNP (pg/mL) | 99 ± 252 | 105 ± 206 | 0.69 |
| Atrial fibrillation during follow-up, % | 4.2 | 5.6 | 0.25 |
| Heart failure during follow-up, % | 2.2 | 2.5 | 0.70 |
| Coronary heart disease during follow-up, % | 2.7 | 4.0 | 0.15 |

*After excluding 37 participants with the diagnosis of atrial fibrillation at baseline.

Video. Feature tracking CMR was used to track LA wall motion in 2- and 4-chamber cine images.